Carisma Therapeutics   Report issue

For profit Phase 1 Phase 3
Founded: Philadelphia PA United States (2016)
Status: Acquired by Sesen Bio (2022)

Organization Overview

First Clinical Trial
2021
NCT04660929
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Carisma Therapeutics | Carisma Therapeutics Inc

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Carisma Therapeutics (0) Acquired (2)

ebi-005 (6 trials)

proxinium (4 trials)

Drugs in Phase 1 Trials (3)

Key: Carisma Therapeutics (0) Acquired (3)

ct-0508 (1 trial)

ebi-031 (1 trial)

vb6-845 (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 13
  • # of Trial APIs: 5